CD HEALTH ALERT: Prevention of Invasive Pneumococcal Disease in Adults: CDC Publishes New Guidance for Use of 15 & 20 Valent Pneumococcal Vaccines

CD News Alert

February 7, 2022

On January 28, 2022, the CDC’s Advisory Committee on Immunization Practices (ACIP) released its recommendations on the use of two new pneumococcal conjugate vaccines (PCV) in adults, the 15 valent PCV15 (VAXNEUVANCE) and the 20 valent PCV20 (PREVNAR 20). The new recommendations are as follows:

Adults aged ≥65 years: Adults aged ≥65 years who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of PPSV23.

Adults aged 19–64 years with certain underlying medical conditions or other risk factors: Adults aged 19–64 years with certain underlying medical conditions or other risk factors who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of PPSV23.

The updated guidance can be found here.